Alert6 days ago 3 min read
FDA warning letter targets large peptide compounder
A widely used compounder was cited for sterility and sourcing violations.
by Editorial team
The letter
The FDA issued a warning letter this week to a large peptide compounding pharmacy serving multiple wellness clinics.
Citations included sterility procedure failures and use of non-pharmaceutical-grade ingredients.
Impact
The compounder has paused production of several product lines pending response.
Clinics that source from this compounder are notifying patients and switching suppliers.
What to do
If you receive notice that your peptide source has changed, ask your prescriber for the new pharmacy's name and credentials.
Keep batch numbers and lot information for any product you have at home.